简体
  • 简体中文
  • 繁体中文
×

热门资讯> 正文

bioAffinity Technology宣布私募定价

2025-08-13 22:11

  • bioAffinity Technologies (NASDAQ:BIAF) announced on Wednesday that it has entered into securities purchase agreements for the purchase and sale of 990 shares of its Series B convertible preferred stock and warrants to purchase approximately 6.7 million shares of common stock.
  • The shares of preferred stock have a stated value of $1,000 per share and are initially convertible into an aggregate of approximately 4.3 million shares of common stock at a conversion price of $0.23 per share. 
  • The private placement warrants will be exercisable following the date on which the company obtains stockholder approval of the exercise thereof at an initial exercise price of $0.352 per share, and expire five years from the original exercise date.
  • The company also announced today it has entered into a warrant exercise agreement with an existing accredited investor to exercise outstanding warrants to purchase 450,000 shares of the company’s shares of common stock that were issued in August 2024.
  • The new warrants will have an exercise price of $0.352 per share and will be initially exercisable on the date that stockholder approval of the exercise of the new warrants is obtained, and will expire five years from the date of such approval.
  • The closing of the private placement and warrant inducement is expected to occur on or about August 14, 2025.
  • The expected aggregate proceeds (before expenses) of the private placement and warrant inducement will be approximately $1.2 million.
  • The company shall use the net proceeds from the private placement and warrant inducement for working capital and general corporate purposes.
  • BIAF -5.07% premarket to $0.26.
  • Source: Press Release

推荐文章

风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
问答大全
（工作日09：30 - 次日05：30）
客户端：
关注我们：
  • 微信公众号二维码

© 2025 深圳市时代华盛网络科技有限公司版权所有 粤ICP备16068286号